Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
about
Differential immunomodulatory effects by Tripterygium wilfordii Hook f-derived refined extract PG27 and its purified component PG490 (triptolide) in human peripheral blood T cells: potential therapeutics for arthritis and possible mechanisms explainInflammation and p53: A Tale of Two StressesSoy Isoflavone Protects Myocardial Ischemia/Reperfusion Injury through Increasing Endothelial Nitric Oxide Synthase and Decreasing Oxidative Stress in Ovariectomized Rats.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain.Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.Platelet IκB kinase-β deficiency increases mouse arterial neointima formation via delayed glycoprotein Ibα shedding.NF-κB as a potential therapeutic target in microbial diseases.Emerging drugs for chronic obstructive pulmonary disease.NF-κB and the link between inflammation and cancer.Apigenin blocks IKKα activation and suppresses prostate cancer progression.Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.p53 and the Carcinogenicity of Chronic Inflammation.The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma.IκB-α: At the crossroad between oncogenic and tumor-suppressive signals.Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-κB and Bcl-2 families.miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways.Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.Ac-SDKP suppresses TNF-α-induced ICAM-1 expression in endothelial cells via inhibition of IκB kinase and NF-κB activation.Involvement of p38MAPK/NF-κB signaling pathways in osteoblasts differentiation in response to mechanical stretch.Angiotensin-(1-7)-mediated Mas1 receptor/NF-κB-p65 signaling is involved in a cigarette smoke-induced chronic obstructive pulmonary disease mouse model.Hypoxia Inducible Transcription Factors, HIF1A and HIF2A, Increase in Aging Mucosal Tissues.Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.Inhibition of NF-κB activation by a novel IKK inhibitor reduces the severity of experimental autoimmune myocarditis via suppression of T-cell activation.
P2860
Q34462745-88096B38-1B20-4E66-9D9F-9BA9B9742CE7Q35103171-BA9C5BAD-4755-4BB9-A2F8-1AF47ECFA44DQ36579199-A262D27E-7EF3-4EAF-8E21-689F40F4DA0EQ36901072-D79FECAD-FCA7-4AA1-BDEA-76BF19FCF584Q36989424-EE942313-2C1F-4ED4-8C8F-E633A8B99C14Q37075277-63E31841-134A-4469-A464-DF7C67E05548Q37127000-56558A51-B83E-4379-86FC-AAB8043C1520Q37981941-DCD75A87-C005-4CB3-8E87-4E839B1F5963Q37984088-826EA7E3-10DC-4D69-898E-7D18240CB0EBQ37995696-80F915C4-6BB3-4664-A4ED-D6E8ADF0734AQ38260580-00E322AB-BB6F-4602-A606-AF2DEFC93A94Q38882099-46BE83DB-E27E-4A43-A166-C0C0C0117501Q38934157-336FE31E-B510-4FC3-B6FA-122D9E72D8E8Q38942433-5DB5E4F0-CFEC-46C6-AAA4-482C80458016Q39207728-46EC96F8-6E03-44D5-996F-1F249EE35AA7Q39931378-84494DF4-E7A4-45F6-953A-51C6719D6185Q41049761-B48C4932-94F7-41EC-BE43-98A4CFB6EF3BQ42246428-4070D027-22BA-442E-8087-4D4D9E42202CQ42261435-809E120D-3045-4E69-A0F4-704C148895BBQ42329928-9D24A5FA-C13F-4D85-A2F4-7A814BC6A2CBQ42797916-A60E7CA2-F828-49A1-B8FA-33DD91F608ACQ47726786-429CD756-BADD-4737-BC4F-8F7EDDD4C629Q50026303-05C065E6-D43B-4B6B-989D-2E50165AF63BQ51009649-D91D54F8-3743-4FFF-80CD-881C61EF3D3FQ54405098-59113E66-E3B7-41D2-8370-36B3E3B96B4B
P2860
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@en
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@nl
type
label
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@en
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@nl
prefLabel
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@en
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@nl
P2093
P2860
P1476
Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.
@en
P2093
Akiko Itai
Jun-ichi Suzuki
Masahito Ogawa
Mitsuaki Isobe
Ryozo Nagai
Susumu Muto
Yasunobu Hirata
P2860
P304
P356
10.1517/13543784.2011.559162
P407
P577
2011-03-01T00:00:00Z